道一把「更安全」放在所有指标之前：更低免疫激活、更低炎症刺激、更低毒性、可重复给药。递送技术不是为了把更多药送进去，而是为了让患者能长期安全地用药。
Safety comes before every other metric at Harmony Tao: lower immune activation, lower inflammatory stimulation, lower cytotoxicity, repeat dosing. Delivery is not about pushing more drug in — it is about letting patients stay on therapy safely, for longer.
肝靶向 LNP 平台的每一代优化，都以「更高表达、更低免疫激活、更低炎症刺激」为验收标准。
Every generation of our liver-targeted LNP platform is judged by three numbers: higher expression, lower immune activation, lower inflammation.
转染效率、细胞毒性、组织表达分布均以对照实验数据呈现；不写没有实测支撑的性能结论。
Transfection efficiency, cytotoxicity and tissue expression are presented as controlled data. We do not claim performance we have not measured.
与长三角、川渝、北方及美国 Biotech 与药企就基因编辑、siRNA、mRNA 项目展开递送层合作。
We partner with biotechs and pharma across China and the US on the delivery layer of gene editing, siRNA and mRNA programs.
道一采用「科学团队 + 四个技术单元 + 商务项目」的扁平结构：脂质化学、递送制剂、生物学评价、AI 数据四条线各自独立又共用同一套数据库。
Harmony Tao runs a flat structure of a scientific founding team, four technical units and a business/programme office: lipid chemistry, formulation, biological evaluation and AI/data — independent, but sharing one database.
新型可电离脂质结构设计、合成与纯化；构建用于被动靶向的 Lipid 分子库。
Design, synthesis and purification of novel ionizable lipids; building the passive-targeting lipid library.
处方筛选、粒径 / 电位 / 包封率等理化参数表征，形成 T-LNP 处方数据库。
Formulation screening plus size, zeta potential and encapsulation efficiency characterisation feeding the T-LNP formulation database.
Lipoeasy® 工具完成的体外细胞转染验证与体内动物药效模型评价。
Cell-level transfection validation with Lipoeasy® and in vivo animal efficacy models.
用体内外实测数据训练预测模型，支撑脂质 / 处方的高效筛选。
Training predictive models on measured in vitro / in vivo data to accelerate lipid and formulation screening.
多肽、蛋白、核酸类药物的纳米递送技术
Nanoscale delivery of peptide, protein and nucleic acid drugs
新型脂质材料结构设计与合成
Structural design and synthesis of novel lipid materials
公司运营、项目评估、项目执行
Company operations, project evaluation and execution
Team information is compiled from company materials; titles and current membership follow company announcements.
